We hypothesized that not only hepatitis and consequent fibrosis but also liver steatosis in the progression of NASH may be triggered or modulated by NLRP3 inflammasome activation. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.